- Previous Close
160.46 - Open
154.00 - Bid --
- Ask --
- Day's Range
152.88 - 157.38 - 52 Week Range
151.44 - 201.92 - Volume
1,282 - Avg. Volume
11,709 - Market Cap (intraday)
73.745B - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
0.35 - EPS (TTM)
4.36 - Earnings Date May 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
www.zoetis.com13,800
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0M3Q.L
View MorePerformance Overview: 0M3Q.L
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0M3Q.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0M3Q.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
26.86%
Return on Assets (ttm)
14.87%
Return on Equity (ttm)
51.14%
Revenue (ttm)
9.26B
Net Income Avi to Common (ttm)
2.49B
Diluted EPS (ttm)
4.36
Balance Sheet and Cash Flow
Total Cash (mrq)
1.99B
Total Debt/Equity (mrq)
143.17%
Levered Free Cash Flow (ttm)
2.37B